Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Equity Compensation Plans	A C E A Therapeutics Inc [Member]	Common Stock	Common Stock Equity Compensation Plans	Treasury Stock	Additional Paid-in Capital	Additional Paid-in Capital Equity Compensation Plans	Additional Paid-in Capital A C E A Therapeutics Inc [Member]	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Noncontrolling Interest
Balance at Dec. 31, 2020	$ 140,731			$ 28		$ (49,464)	$ 1,172,346			$ 520	$ (958,279)	$ (24,420)
Balance, shares (in shares) at Dec. 31, 2020				275,286		7,568
Issuance of common stock, net	42,209	$ 5,394		$ 1			42,208	$ 5,394
Issuance of common stock, net (in shares)				3,901	500
Issuance of common stock upon exercise of warrants	9,050						9,050
Issuance of common stock upon issuance of warrants (in shares)				2,550
Other acquisitions, license agreements and investments paid in equity	7,500						7,500
Other acquisitions, license agreements and investments paid in equity (in shares)				851
Changes to noncontrolling interests from increased ownership in Scilex Holding							(23,963)					23,963
Changes to noncontrolling interests from increased ownership in Scilex Holding (in shares)				2,567
Stock-based compensation	23,660						23,660
Foreign currency translation adjustment	(75)									(75)
Net income (loss)	2,418										2,510	(92)
Balance at Mar. 31, 2021	230,887			$ 29		$ (49,464)	1,236,195			445	(955,769)	(549)
Balance, shares (in shares) at Mar. 31, 2021				285,655		7,568
Balance at Dec. 31, 2020	140,731			$ 28		$ (49,464)	1,172,346			520	(958,279)	(24,420)
Balance, shares (in shares) at Dec. 31, 2020				275,286		7,568
Foreign currency translation adjustment	613
Net income (loss)	(164,281)
Balance at Jun. 30, 2021	185,535			$ 30		$ (49,464)	1,356,853			1,133	(1,122,384)	(633)
Balance, shares (in shares) at Jun. 30, 2021				297,975		7,568
Balance at Mar. 31, 2021	230,887			$ 29		$ (49,464)	1,236,195			445	(955,769)	(549)
Balance, shares (in shares) at Mar. 31, 2021				285,655		7,568
Issuance of common stock, net	50,752	1,377		$ 1			50,751	1,377
Issuance of common stock, net (in shares)				5,886	300
Other acquisitions, license agreements and investments paid in equity	5,378		$ 42,168				5,378		$ 42,168
Other acquisitions, license agreements and investments paid in equity (in shares)			5,519	615
Stock-based compensation	20,984						20,984
Foreign currency translation adjustment	688									688
Net income (loss)	(166,699)										(166,615)	(84)
Balance at Jun. 30, 2021	185,535			$ 30		$ (49,464)	1,356,853			1,133	(1,122,384)	(633)
Balance, shares (in shares) at Jun. 30, 2021				297,975		7,568
Balance at Dec. 31, 2021	78,129			$ 32		$ (49,464)	1,513,758			1,026	(1,386,604)	(619)
Balance, shares (in shares) at Dec. 31, 2021				314,573		7,568
Issuance of common stock, net	164,437	132		$ 6			164,431	132
Issuance of common stock, net (in shares)				58,875	438
Acquisitions consideration paid in equity	4,435						4,435
Acquisitions consideration paid in equity (in shares)				1,282
Stock-based compensation	20,854						20,854
Foreign currency translation adjustment	(1,249)									(1,249)
Net income (loss)	(40,540)										(40,815)	275
Balance at Mar. 31, 2022	226,198			$ 38		$ (49,464)	1,703,610			(223)	(1,427,419)	(344)
Balance, shares (in shares) at Mar. 31, 2022				375,168		7,568
Balance at Dec. 31, 2021	78,129			$ 32		$ (49,464)	1,513,758			1,026	(1,386,604)	(619)
Balance, shares (in shares) at Dec. 31, 2021				314,573		7,568
Foreign currency translation adjustment	837
Net income (loss)	(260,017)
Balance at Jun. 30, 2022	135,763			$ 18		$ (49,464)	1,826,810			837	(1,646,178)	3,740
Balance, shares (in shares) at Jun. 30, 2022				436,419		7,568
Balance at Mar. 31, 2022	226,198			$ 38		$ (49,464)	1,703,610			(223)	(1,427,419)	(344)
Balance, shares (in shares) at Mar. 31, 2022				375,168		7,568
Issuance of common stock, net	104,169	$ 668		$ 6			104,163	$ 668
Issuance of common stock, net (in shares)				60,707	544
Changes to noncontrolling interests from increased ownership in Scilex Holding	4,776			$ (26)								4,802
Stock-based compensation	18,369						18,369
Foreign currency translation adjustment	1,060									1,060
Net income (loss)	(219,477)										(218,759)	(718)
Balance at Jun. 30, 2022	$ 135,763			$ 18		$ (49,464)	$ 1,826,810			$ 837	$ (1,646,178)	$ 3,740
Balance, shares (in shares) at Jun. 30, 2022				436,419		7,568